Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation

Claire A. Irving, Vaughan Carter, Andrew R. Gennery, Gareth Parry, Massimo Griselli, Asif Hasan, C. Richard Kirk

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Background De novo donor-specific HLA antibodies (DSA) are a risk for poor graft outcomes, but there is little evidence of their long-term effect in pediatric cardiac transplantation or of the effect of transient versus persistent DSA found using newer antibody testing methods. Methods Archived serum samples were obtained from patients <18 years of age who underwent primary cardiac transplantation during the period from 1996 to 2009. Luminex antibody testing was performed at 3 months, 6 months and 1 year post-transplant, and then annually. Outcomes including cardiac allograft vasculopathy (CAV), rejection and graft loss were correlated with the presence or absence of DSA or non-donor-specific HLA (non-DSA) antibodies. Results Six hundred ninety-one samples from 108 patients, with mean age at transplant of 7.4 (0.1 to 15.9) years and mean follow-up 8.2 (1.9 to 15.7) years, were studied. Forty-three (40%) patients had DSA (which were persistent in 58%), 41 (38%) had non-DSA (persistent in 46%) and 24 (22%) had no antibodies. In those with DSA, 30% had Class I antibodies, 47% Class II and 23% both Class I and II, whereas, in the subgroup with persistent DSA, 88% had Class II antibodies. There were 14 cases of graft loss, 9 of these in patients with persistent DSA. All had Class II antibodies. There was an increased incidence of CAV, rejection and graft loss in those with persistent DSA. Outcomes were similar between the group with non-DSA antibodies and the group with no antibodies. Conclusions De novo HLA antibodies are detectable post-transplant in the majority of patients, but non-DSA and transient DSA do not appear to be associated with poor outcomes. Patients with persistent DSA, especially those with Class II DQ antibodies, have worse survival.

Original languageEnglish (US)
Pages (from-to)1310-1317
Number of pages8
JournalJournal of Heart and Lung Transplantation
Issue number10
StatePublished - Oct 2015
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015 International Society for Heart and Lung Transplantation. All rights reserved.


  • HLA antibodies
  • donor-specific
  • graft outcomes
  • pediatric cardiac transplantation


Dive into the research topics of 'Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation'. Together they form a unique fingerprint.

Cite this